Systems for detecting and quantifying nucleic acids
11156582 · 2021-10-26
Assignee
- GEORGIA STATE RESEARCH FOUNDATION, INC. (Atlanta, GA, US)
- The United States Government As Represented By The Department Of Veterans Affairs (Washington, DC)
Inventors
Cpc classification
G01N27/48
PHYSICS
International classification
G01N27/48
PHYSICS
Abstract
This invention is based, in part, on our discovery of an essentially one-step, label-free system comprising a sensing unit having a redox current reporter and a nucleic acid sequence complementary to that of a target nucleic acid of interest or sufficiently complementary to that of the target nucleic acid or a sequence therein to specifically bind the target nucleic acid. The sensing unit is bound to an electroconductive substrate (e.g., a carbon- or metal-containing microelectrode (e.g., a gold microelectrode)), and the system includes a signal amplification mechanism that does not rely upon a redox enzyme and thereby overcomes a fundamental limitation of microelectrode DNA sensors that fail to generate detectable current in the presence of only small amounts of a target nucleic acid.
Claims
1. A system for detecting a target nucleic acid in a sample, the system comprising an electroconductive substrate; a sensing unit that is bound to the substrate, wherein the sensing unit comprises a redox current reporter and a sequence-specific nucleic acid, wherein the sequence-specific nucleic acid comprises a nucleic acid sequence that is sufficiently complementary to that of the target nucleic acid or a sequence therein to specifically bind the target nucleic acid, wherein the sequence-specific nucleic acid is a single nucleic acid strand, is bound to the substrate, and is not bound to the substrate via a separate nucleic acid strand, wherein the redox current reporter is linked to the sequence-specific nucleic acid; and a coreactant.
2. The system of claim 1, wherein the target nucleic acid is a microRNA (miRNA) or a precursor thereof.
3. The system of claim 1, wherein the electroconductive substrate comprises a carbon- or metal-containing microelectrode.
4. The system of claim 3, wherein the electroconductive substrate is fashioned as a microelectrode having a radius or dimension of about 0.1-100 μm, a nanoelectrode having a radius or dimension below 0.1 micron, or a macroelectrode having a radius or dimension above 100 micron.
5. The system of claim 1, wherein the sensing unit is covalently bound to the substrate.
6. The system of claim 1, wherein the sensing unit is bound to the substrate through a thiolate moiety.
7. The system of claim 1, further comprising alkanethiolate moieties bound to the substrate to passivate the system and thereby reduce non-specific signals.
8. The system of claim 1, wherein the redox current reporter comprises a molecule capable of undergoing oxidation, thereby transferring electrons to the substrate and generating an oxidized redox current reporter.
9. The system of claim 1, wherein the redox current reporter comprises a molecule capable of undergoing reduction, thereby capturing electrons from the substrate and generating a reduced redox current reporter.
10. The system of claim 9, wherein the coreactant is capable of oxidizing the reduced redox current reporter.
11. The system of claim 1, w8herein the nucleic acid sequence is 17-27 nucleotides in length.
12. The system of claim 1 further comprising a common buffer in which the coreactant is contained.
13. The system of claim 1, wherein the coreactant is a reductant selected from the group consisting of oxalic acid (C.sub.2H.sub.2O.sub.4), formic acid (HCOOH), ascorbic acid (C.sub.6H.sub.8O.sub.8), a compound comprising an Sn.sup.2+ ion or Fe.sup.2+ ion, hydrazine, tris-(2-carboxyethyl) phosphine hydrochloride (TCEP), and any other reagent that will reduce an oxidized redox current reporter; or an oxidant selected from the group consisting of oxygen, hydrogen peroxide and other reactive oxygen species, a compound comprising an Fe.sup.3+ ion, a compound comprising ClO.sub.4.sup.−, BO.sub.3.sup.−, MnO.sub.4.sup.−, SO.sub.5.sup.2−, S.sub.2O.sub.8.sup.2−, HSO.sub.5.sup.−, ClO.sub.2.sup.− or other halogen-containing anions, and any other reagent that will oxidize a reduced redox current reporter.
14. The system of claim 1, wherein the sensing unit lacks a redox enzyme.
15. The system of claim 1, wherein the system is configured for high throughput screening of a plurality of nucleic acids.
16. The system of claim 15, wherein the system comprises a plurality of sensing units, with a first sensor designed to detect a first nucleic acid and a second sensor designed to detect a second nucleic acid, wherein levels of expression of the first and second nucleic acids together signify the presence of a disease state.
17. A method of detecting a target nucleic acid in a sample, the method comprising: providing a sample comprising nucleic acids obtained from a subject or from a patient; and exposing the sample to the system of claim 1.
18. A method of making the system of claim 1, the method comprising (a) providing an electroconductive substrate; (b) immersing the substrate in a solution comprising sensing units for a time sufficient to allow the sensing units to self-assemble on the surface of the substrate, thereby generating a probe-functionalized substrate; (c) immersing the probe-functionalized substrate in a solution comprising passivating agents for a time sufficient to allow the agents to self-assemble on the surface of the substrate.
19. The method of claim 18, wherein the sensing unit comprises a sulfhydryl group, alkyne, or any functional group that provides precursors to bind to the electroconductive substrate; wherein the passivating agents comprise a sulfhydryl group or are an alkanethiol; or wherein the step of immersing the probe-functionalized substrate in a solution comprising inert thiol moieties further comprises heating and cooling the solution.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
DETAILED DESCRIPTION
(9) A system as described herein is illustrated in
(10) Sensing Unit Electroconductive Substrates:
(11) The electroconductive substrate can comprise a carbon- or metal-containing microelectrode (e.g., a gold microelectrode). The sensing unit can be bound to the substrate non-covalently, or covalently (e.g., through a thiolate moiety), and the substrate can further be bound to moieties that do not contain sensing units (e.g., alkanethiolate). These “small non-sensing” moieties passivate the unoccupied sites on the substrate and thereby reduce non-specific signals.
(12) Solutions and Coreactants:
(13) In use, the sensing unit is immersed in a solution comprising a coreactant, and optionally, a common buffer.
(14) In certain embodiments, the redox current reporter can include a molecule capable of undergoing oxidation and transferring electrons to the substrate, and the coreactant can be a reductant. The reductant can be an agent that is capable of reducing the oxidized redox current reporter. For examples, the reductant can be oxalic acid (C.sub.2H.sub.2O.sub.4), formic acid (HCOOH), ascorbic acid (C.sub.6H.sub.8O.sub.8), tris-(2-carboxyethyl) phosphine hydrochloride (TCEP), or any other reagent that will reduce the oxidized redox current reporter. In alternative embodiments, the redox current reporter can include a molecule capable of undergoing reduction and transferring electrons from the substrate, and the coreactant can be an oxidant that is capable of oxidizing the reduced redox current reporter.
(15) Common buffers include but are not limited to phosphate buffered saline, TAPS (3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonic acid), bicine, tricine, TAPSO, HEPES, Tris, TES, MOPS, PIPES, cacodylate, SSC, MES, or succinic acid buffer.
(16) Target Nucleic Acids:
(17) Target nucleic acids can be microRNAs (miRNAs) or a precursor thereof, genomic DNA, cellular DNA, acellular DNA, microorganismal DNA, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), viral RNA, or a small nuclear RNA (snRNA). The present systems can be configured to detect the presence or absence of one or more single base mutations in a double-stranded target nucleic acid molecule and include a sensing unit that is designed to hybridize with the double-stranded and denatured target nucleic acid molecule in a reaction which proceeds at approximate thermodynamic equilibrium when no single base mutations are present in the double-stranded target nucleic acid molecule. The point mutations detected can be deletions, insertions, substitutions or single nucleotide polymorphisms (SNPs) in a target nucleic acid. Biologically significant or pathogenic processes may be indicated by a single base alteration or mutation within a target nucleic acid.
(18) The target nucleic acids can be obtained from any biological sample. For example, the sample can be obtained from a human subject or other mammal such as a domesticated animal or livestock. The sample can also be obtained from cells (e.g., the cells of a cell line) or tissue maintained ex vivo in tissue culture or in a frozen or other preserved state. The sample may include, for example, blood, plasma, serum, bone marrow, cerebrospinal fluid, urine, or any diseased tissue (e.g., tissue obtained from a tumor biopsy, by lavage, or from a ductal system).
(19) In certain embodiments, the present systems can be configured to detect, or quantify, a target nucleic acid that is present in a sample at, or below, a low level. The low level can be a millimolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 mM), a micromolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 μM), a nanomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 nM), a picomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 pM), a femtomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 fM), an attomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 aM), a zeptomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 zM), a yoctomolar level (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 yM), or a level therebetween.
(20) In some embodiments, the present systems can be embedded in or otherwise part of a paper-based or polymer-based diagnostic tool, such as a lateral flow device or printed electrode arrays. A paper-based diagnostic tool can include a reaction with a visual readout, such as a paper-based microfluidic device or a lateral flow test based on the wicking of a sample through a matrix or other interface treated with biochemical reagents that are known in the art.
(21) The present systems can be configured with a plurality of sensing units (a first sensing unit designed to detect a first target nucleic acid; a second sensing unit designed to detect a second target nucleic acid; and so forth) and can therefore by used in high throughput screening assays.
(22) Quantitative Methods:
(23) The present system can be configured to determine the level (e.g., concentration) of the target nucleic acid in a sample. The system can be used in connection with various suitable quantitative methods that are known for detecting or quantifying nucleic acids (e.g., Dong et al. Chem. Rev. 113:6207, 2013; Hunt, et al., Annu. Rev. Anal. Chem. 8:217, 2015).
(24) In certain embodiments, the system can be calibrated with one or more standard solutions, and each of the standard solutions can contain a known concentration of the target nucleic acid. By measuring the signals of the system (e.g., the generated current) in the standard solutions, a quantitative correlation between the signal and the concentration of the target nucleic acid can be generated. The quantitative correlation can be used to determine the level of the target nucleic acid in the sample from the measured signal of the system in the sample.
(25) Measurement of Signals:
(26) During the detection or quantification of the target nucleic acid, the signal (e.g., current) generated by the present system can be measured or analyzed by various suitable techniques. The signal can be measured by amperometry, chronoamperometry, differential pulse voltammetry, cyclic voltammetry, square wave voltammetry, or any combination thereof.
(27) Diagnostic Methods:
(28) A system as described herein can include a first sensor designed to detect a first nucleic acid and a second sensor designed to detect a second nucleic acid, wherein levels of expression of the first and second nucleic acids together signify the presence of a disease state. For descriptions of cell-free miRNAs and a description of serum miRNAs as biomarkers for cancer diagnosis, see Brase et al. Molecular Cancer 9:306, 2010, Zen (Zen et al., Med. Res. Rev. 32(2):326-348, 2012, and Zhang (Zhang et al., World J. Gastroenterol. 21(34):9853-9862, 2015).
(29) More specifically, the systems described herein can include sensing units configured to detect miRNA-155, miRNA-210, and miRNA-21, and such systems are useful in diagnosing diffuse large B cell lymphoma, as the expression levels of miRNA-155, -210, and -21 are higher in the sera of patients who have developed diffuse large B cell lymphoma (Lawrie et al., Br. J. Haematol 141:672, 2008). High serum levels of miRNA-21 are also associated with relapse-free survival (Dong et al., Chemical Reviews 113:6207, 2013). Accordingly, the present methods can be used to determine the prognosis for a patient with diffuse large B cell lymphoma, with persistently high levels of miRNA-21 (but not miRNA-155 or miRNA-210) indicating an increased likelihood of relapse-free survival. When a sensing unit is “configured to detect” a targeted nucleic acid (i.e., a nucleic acid of interest), the sensing unit will contain a nucleic acid sequence that is the reverse and complement of the target or a portion thereof, and specific binding between the targeted nucleic acid and the nucleic acid in the sensing unit allows the targeted nucleic acid to be selectively bound and thereby detected.
(30) In another embodiment, the systems include sensing units configured to detect let-7a, miRNA-155 and miRNA-195 in diagnosing breast cancer, and/or to distinguish the breast cancer from benign disease (Heneghan et al., Ann. Surg. 251:499, 2010; Zhu et al., BMC Res. Notes 2:89, 2009).
(31) In another embodiment, the systems include sensing units configured to detect miRNA-29, miRNA-92a, miR-17-3p and miR-92 in diagnosing colon cancer, and/or to distinguish the colon cancer from benign disease (Huang et al., Int. J. Cancer 127:118, 2010; Ng et al., Gut. 58:1375, 2009).
(32) In another embodiment, the systems include sensing units configured to detect miR-17-5p, miR-21, miR-106a, miR-106b and let-7a in diagnosing gastric cancer, and/or to distinguish the gastric cancer from benign disease (Tsujiura et al., Br. J. Cancer 102:1174, 2010).
(33) In another embodiment, the systems include sensing units configured to detect miRNA-92a in diagnosing leukemia, and/or to distinguish the leukemia from benign disease (Tanaka et al., PLOS ONE 4:e5523, 2009).
(34) In another embodiment, the systems include sensing units configured to detect miRNA-25, miRNA-223, miR-486, miR-30d, miR-1 and miR-499 in diagnosing lung cancer, and/or to distinguish the lung cancer from benign disease (Chen et al., Cell Res. 18:997, 2008; Hu et al., Clin. Oncol. 28:1721, 2010).
(35) In another embodiment, the systems include sensing units configured to detect miR-31 in diagnosing oral cancer, and/or to distinguish the oral cancer from benign disease (Liu et al., Oral Dis. 16:360, 2010).
(36) In another embodiment, the systems include sensing units configured to detect miRNA-21, miRNA-92, miRNA-93, miRNA-126, miRNA-29a, miRNA-155, miRNA-127, miRNA-99b in diagnosing ovarian cancer, and/or to distinguish the ovarian cancer from benign disease (Resnik et al. Gynecol. Oncol. 112:55, 2009).
(37) In another embodiment, the systems include sensing units configured to detect miRNA-210, miR-21, miR-155, miR-196a in diagnosing pancreatic cancer, and/or to distinguish the pancreatic cancer from benign disease (Ho et al., Transl. Oncol. 3:109, 2010; Wang et al., Cancer Prev. Res. (Phila. Pa.) 2:807, 2009).
(38) In another embodiment, the systems include sensing units configured to detect miRNA-141, miRNA-375 in diagnosing prostate cancer, and/or to distinguish the prostate cancer from benign disease (Mitchell et al., Proc. Natl. Acad. Sci. USA 105:10513, 2008; Brase et al., Int. J. Cancer 128:608, 2011).
(39) In another embodiment, the systems include sensing units configured to detect miRNA-184 in diagnosing squamous cell carcinoma, and/or to distinguish the squamous cell carcinoma from benign disease (Wong et al., Clin. Cancer Res. 14:2588, 2008).
(40) In another aspect, the invention features methods of making the systems described herein, and the assembled systems or component parts thereof can be packaged as a kit together with instructions for use.
EXAMPLES
(41) The invention will be further illustrated in the following non-limiting examples. The following methods and techniques were used in the studies described below.
(42) Reagents and Materials:
(43) All solutions were prepared with RNase/DNase-free, ultrapure distilled water (Invitrogen). The following reagents were used as received: phosphate buffered saline (PBS; pH 7.4; 10×; Life Technologies), magnesium chloride hexahydrate (99-102%; Sigma-Aldrich), guanidine hydrochloride (≥99%; Sigma-Aldrich), tris-(2-carboxyethyl) phosphine hydrochloride (TCEP; ≥98%; Sigma-Aldrich), and 6-mercapto-1-hexanol (97%; Sigma-Aldrich). Thiolated, methylene blue-conjugated DNA (thio-MB-DNA) and micro RNAs (miR) were purchased from Biosearch Technologies (Novato, Calif.) and purified by RP-HPLC. The sequences of DNA probes and single-stranded miRNAs used in this work are given in Table 1.
(44) Preparation of the Electrode and DNA Monolayer Assembly: Gold microelectrode fabrication was carried out using a well-established method. Briefly, a 50 μm-diameter gold wire was attached to a tugsten rod using conductive silver epoxy. The gold-tungsten assembly was then inserted into a soda lime glass capillary and then the gold wire was sealed into the capillary using a natural gas-oxygen flame. The other end of the assembly was secured with a resin epoxy. Finally, the excess insulating glass is removed through manual polishing on sand paper (from rough to find grit) to expose a gold wire resulting in a microdisk electrode with a 50 μm diameter. The gold electrode was polished carefully to a mirror surface on a 1200-grit sand paper followed by an aqueous slurry of 0.05 μm diameter alumina particles and then successively washed in an ultrasonic cleaner with water to remove excess polishing particles. Finally, the gold electrode was electrochemically polished by scanning the potential from −0.5 to +1.5 V in 0.1 M H2SO4 at a scan rate of 0.1 V s-1 for 10 cycles. The cleaned gold electrode was thoroughly washed with D.I. water and ethanol and dried under flowing nitrogen.
(45) Prior to surface modification, 1 μL of 200 μM thio-MB-DNA was mixed with 2 μL of 25 mM TCEP in a 200-4, PCR tube. The tube was incubated for 20 minutes at room temperature (21° C.) for reduction of disulfide bonds and to reduce the MB-moiety of the DNA probe. The solution was then diluted to a total volume of 200 μL in a high salt buffer (10 mM potassium phosphate, 30 mM sodium phosphate, 1.55 M sodium chloride and 1 mM magnesium chloride, pH 7.2) to a final concentration of 1 μM. For immobilization, the previously cleaned gold electrode was transferred directly to the diluted and reduced thiol-MB-DNA solution and incubated for 16 h at room temperature in the dark. Following the formation of a self-assembled monolayer (SAM), excess thio-MB-DNA physically adsorbed on the electrode surface was removed via a room temperature-deionized water rinse (˜30 s). The surface was then passivated by immersing the electrode into a 1 mM mercaptohexanol in high salt buffer for 2 h. For optimal surface modification, the sensor was placed in a hybridization buffer (0.25 mM potassium phosphate, 0.75 mM sodium phosphate, 39 mM sodium chloride and 10 mM magnisium chloride, pH 7.1) and heated indirectly via a water bath of 75° C. for 10 min. After the surface cooled down, another passivation with 1 mM mercaptohexanol was performed for 1 h. Unless otherwise noted, all solutions used in the studies described below were carried out in hybridization buffer at pH 7.1. For convenient surface regeneration, hybridized sensors were rinsed in 4 M GHCl for 30 s followed by a 3-hour incubation in hybridization buffer.
(46) Electrochemical Measurements:
(47) Electrochemical measurements were performed using a Gamry Reference 600 electrochemistry workstation (Gamry Instruments, Warminster, Pa.) with a Ag/AgCl(s)/KCl(sat) reference electrode (Bioanalytical Systems, Inc.) and a gold working electrode. All potentials are reported relative to the saturated Ag/AgCl reference electrode. Electrochemical measurements were performed in hybridization buffer using cyclic voltammetry (CV) from −0.6 V to +0.2 V, or square wave voltammetry (SWV) with a 50 mV amplitude signal, over the range from −0.6 V to +0.1 V versus Ag/AgCl reference. The oxidative peak of MB was detected by CV or SWV at −200 mV (vs Ag/AgCl) at the 10-minute time point. MB was chosen as the redox tag due to its excellent shelf life and robust electrochemical response in serum compared to other redox tags, such as ferrocene (Kang et al., J. Anal. Chem. 81:9109, 2009). The SWV response of each sensor was quantified as follows: (1) background (without target) and signal (with target) SWV data sets were collected; (2) difference traces were generated by subtraction of the two data sets; (3) baseline was corrected with B-spline generated baseline in Origin 8 using two regions: −0.60 to −0.40 V and −0.08 to +0.10 V; (4) traces were integrated from −0.40 to −0.08 V. To prepare calibration graphs, we report the average and deviations of two measurements on two different sensors for relatively high miR-122 concentrations from 10 fM to 0.5 nM, while for the low miR-122 concentrations of 0.1 fM and 1 fM the average of three measurements on two different sensors is reported. Selectivity tests with mismatched sequences were made in the same manner by substituting miR-122-3p or miR 22B for miR-122. Prior to the measurement of colitis mouse serum, a serum aliquot of 2 was heated for 15 minutes at 95° C., followed by centrifuging to collect sample. Then, the serum aliquot was diluted in a 20 μL buffer solution for easy handling and to make the current signal comparable with calibration measurements at the time for detection. The sensor was incubated for 10 minutes at room temperature prior to data collection.
(48) Study Overview:
(49) The work below demonstrates a system having high selectivity and discrimination between two similar family sequences: miR-122-3p, present in serum, and a synthetic RNA sequence mismatched by two nucleotides. Interference, such as the nonspecific adsorption that is a common concern in sensor development, is reduced to negligible levels by adopting a multi-step surface modification strategy. Importantly, unlike qRT-PCR, the microelectrochemical sensor offers a direct absolute quantitative readout that is amenable to clinical and in-home or point-of-care applications. The sensor design is flexible, as it can be tailored to detect different nucleic acids (e.g., miRNAs) of interest, and the system can be configured for high throughput detection of nucleic acids (e.g., miRNAs), including those serving as disease biomarkers.
(50) miRNA-122 has a unique sequence and is expressed in liver and conserved in vertebrates (Zhang et al., Clin. Chem., 56:1830, 2010). Down-regulation is linked to hepatocellular carcinoma (HCC) and up-regulation is related to gastrointestinal disorders (Starkey Lewis et al., Hepatology, 54:1767, 2011; Coulouarn et al., Oncogene 28:3526, 2009). A self-hybridized, three-stem loop structure DNA sequence is designed following previous report by Plaxco and coworkers as a recognition probe (Xiao et al., J. Am. Chem. Soc., 131:15311, 2009). The sensing unit includes a sequence that is complementary to that of the target miR-122 and methylene blue (MB) as a redox current reporter. To boost the low current associated with a small effective sensor surface, we introduce a chemical reaction mechanism following electron transfer reaction (Flynn et al., Langmuir, 19:10909, 2003) using the reductant TCEP (tris-(2-carboxyethyl) phosphine hydrochloride) in the solution surrounding the sensing units that reduces the oxidized MB in situ (Labib et al., Anal. Chem., 87:1395, 2015). When the sequence-specific portion of the sensing unit recognizes its target nucleic acid in a sample, the redox current reporter (MB in this example) is freed to move nearer the electroconductive substrate, where it is cyclically oxidized electrochemically and reduced chemically by the reductant. This process amplifies the signal (Furst et al., Polyhedron, 84:150, 2014; Lapierre-Devlin et al., Nano Lett., 5:1051, 2005; Fang and Kelley, Anal. Chem., 81:612, 2009). Moreover, with our multi-step surface modification procedure, interference signals caused by non-specific adsorption and surface-bound redox current reporters are reduced to negligible levels. These interference signals are a well-known technical barrier for sensor development. Compared to other sensor-based detection methods, the signal amplification and background reduction we have achieved produce reproducible and reusable systems for rapid, quantitative, and easy (one-step) nucleic acid detection, even where the target nucleic acid is present at extremely low levels.
(51) The principle of signal generation is illustrated in
(52) TABLE-US-00001 Sequence (Abbrevi- Sequence, listed Name ation) 5′ to 3′ Triple- (DNA) /C6 SS/ GGA GTG TTT TTT stem DNA TTC GTG TTT GTT TTT TCA probe AAC ACC ATT GTC ACA CTC CAT TTT TTT TTT TTG ACA ATG /MB/ (SEQ ID NO: 1) mmu-miR- (miR-122) UGG AGU GUG ACA AUG GUG 122 UUU G (SEQ ID NO: 2) mmu-miR- (miR-122- AGU GUG AUA AUG GCG UUU 122-3p 3p) (SEQ ID NO: 3) 2mismatch- (miR 22B) UGG AGU GUG AUA AUG GCG 22Base UUU G (SEQ ID NO: 4)
(53) The triple-stem DNA probe (SEQ ID NO:1) is shown with the recognition sequence underlined. The target sequence is miR-122 (SEQ ID NO:2), and the mismatched sequences (miR-122-3p and miR 22B; SEQ ID NO:3 and SEQ ID NO:4, respectively) are shown with the mismatched nucleotides double underlined.
(54) To design other sensing units to detect different miRNAs, the binding sequence (i.e., the sequence complementary to a target sequence) can be conveniently replaced. The base (as described further below) that sufficiently binds to the binding sequence can also be adjusted accordingly, so that in the absence of the target miRNA, the probe will self-hybridize into three distinct, short-base-pair stems that form a discontinuous double helix (see the left-hand side of
(55) We have developed a multi-step surface modification strategy to optimize the sensor surface and minimize background ET current. Most of the current electrochemical sensors allow for nonspecific adsorption to the substrate, which is detrimental because it induces interference signals that limit quantification, particularly for target nucleic acids at low abundance. The MB oxidation peak at −200 mV indicates a non-ideal surface after the commonly adopted one-step modification. It is rather common to have non-ideal surface packing with defect sites (“pin holes”) in self-assembled monolayers. The redox current reporters can then interact with the electrode for ET after the first passivation step, generating target-independent background current. To improve the quality of the passivating monolayer and supress background current, we applied a heating/cooling cycle that allows rearrangement of the thiolates on the surface of the electroconductive substrate. After a second passivation step with the same inert thiols, baseline-level non-faradic charging current, which indicates an almost ideal surface modification, was achieved in both cyclic voltammetry (CV) and square wave voltammetry (SWV) measurements (blue curves in
(56) A major limitation associated with surface-based electrochemical sensors is that the signal intensity depends on the surface coverage of probes. Once a MB molecule is oxidized at a given potential, it loses ET activity to generate the detection signal until reactivated via reduction. To enhance the sensitivity, we introduce a chemical reagent (reductant) in bulk solution that reduces the oxidized MB in situ at the detection potential. As shown in
(57) The faradic ET current signal resulting from the target recognition can be quantified and differentiated from background current (e.g., capacitive charging-discharging) at the surface of the electroconductive substrate under optimized measurement conditions. The observed CV features at different scan rates are characteristic of electrodes at the transition size range between macroelectrodes and ultramicro/nanoelectrodes. At relatively low scan rates (1 V/s or lower), the anodic current in CVs (
(58) The microelectrode sensor was further challenged for the quantification of miR-122 in phosphate buffer solution at pH 7.1. As shown in
(59) The CVs, on the other hand, are better suited as diagnostic tool for method development. Previous studies could not take advantage of CVs because the current signal is generally too low to be detected. Both CV and SWVs were recorded at the mean time for parallel analysis and method validation. A large dynamic range (sub fM to nM) is established that could be further extended if necessary by the optimization in sensor design and measurement parameters.
(60) Remarkably, the background current can be recovered repeatedly after each target miRNA measurement (bundled black curves in
(61) A langmuir isotherm-type curve was observed by plotting the integrated current signal from SWV as a function of miRNA-122 concentration as the calibration curve (
(62) It is important for method validation and quantitative analysis that the sensing units can be conveniently regenerated, although it might not be critical for practical applications. The negligible, baseline-level background current can be regenerated after a 30-s room temperature wash with 4 M GHCl followed by a 3-h incubation in buffer solution repeatedly (
(63) We evaluated the specificity of the sensing unit with two physiological analogs: a two-base mismatched miR-122-3p with 18 bases and a synthetic two-base mismatched miR 22B of 22 bases that has the same length as the target miR-122. Essentially no response was observed in the presence of 200 pM miR-122-3p or miR 22B even after a 30-minute incubation. To affirm the efficiacy of this exact sensor, with a 10-fold lower miR-122 (20 pM), the signal raised substantially in 10 minutes. We believe the superior discrimination of mismatched bases at room temperature results from the distinct thermodynamic properties in the triple-stem structure regardless of the electrochemistry signal amplification mechanism. The location of the mismatches in the physiological analogs (i.e., in the middle of the sequences or toward the end), the identity of the mismatched bases as well as the length of the nonspecific sequences are factors to consider in the design of probes for other nucleic acids.
(64) To illustrate the efficacy of the sensing unit in a complicated matrix and to mimic detection in real point-of-care settings, we tested a serum sample from a colitic mouse. The expected anodic current from the cyclical oxidation of MB and reduction by TCEP upon binding with target miRNAs was observed at 10 minutes in a diluted serum sample. The results suggest that the signal generation mechanism remains effective in the complex physiological matrix. A heating treatment of the serum sample seemed to be required because the miRNAs are either stabilized by proteins or encapsulated in vesicles in serum/blood. Therefore, the curve (without heating) illustrates the resistance of the sensor detection mechanism to the complicated matrix including nonspecific adsorption of proteins and lipids in physiological samples.
(65) To demonstrate that common reductants other than TCEP could also be used, the sensor was tested using vitamin C in the detection of miR-122. Following the same procedure of TCEP analysis, similar sensor performance was obtained.
(66) In summary, we used a common reductant, TCEP, and the target sequence miR-122 as a model system to demonstrate the sensor efficacy evaluated by potential sweeping CV and pulsed SWV techniques. As a benefit of the multi-step surface modification method, background current was minimized to the baseline level. Combining the pristine baseline (without target miR-122) and signal amplification by TCEP, we demonstrated the detection of miR-122 within minutes at an extremely low level with a wide detection range from 0.1 fM to 0.5 nM. The amplified current signal enabled one-step detection by CV at microelectrode sensors previously inaccessible. The combined diagnostic power in CV and the great sensitivity in SWV are highly advantageous in the present methods and in parameter optimization. Moreover, we could quantify the absolute miRNA abundance by direct electrochemical readouts, which is significant for biomedical research and bodes well for clinical and in-home or point-of-care applications. The sensing unit exhibited superior mismatch discrimination owing to the three-stem double helix design that has been validated in macroscopic electrochemical DNA sensors. The sensing unit preserves its function in diluted mouse serum for detection of miR-122 and exhibits outstanding resistance to interferences present in serum The excellent stability and reproducible surface regeneration with GHCl further enables systematic and quantitative analysis. The sensing unit design is generalizable for other nucleic acid sequences.
(67) We further studied the kinetics of the sensor in detection of miR-122 (
(68) Given that the sensing unit was developed on a small scale electrode, the established platform is promising as a high-throughput system, including for use in detecting miRNA signatures as disease biomarkers or, over a longer term, determining miRNA signatures to complement existing techniques such as qRT-PCR while offering direct quantification.